Jennison Associates’s Denali Therapeutics DNLI Stock Holding History

Jennison Associates’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-45,445	Closed	-$660K	–	601
2025 Q3	$660K	Buy	+45,445	New	+$653K	﹤0.01%	513
2022 Q1	–	Sell	-224,184	Closed	-$10M	–	652
2021 Q4	$10M	Sell	224,184 -4,238	-2%	-$201K	0.01%	442
2021 Q3	$11.5M	Sell	228,422 -146,090	-39%	-$8.23M	0.01%	434
2021 Q2	$29.4M	Hold	374,512	–	–	0.02%	316
2021 Q1	$21.4M	Sell	374,512 -3,000	-0.8%	-$201K	0.02%	347
2020 Q4	$31.6M	Sell	377,512 -6,215	-2%	-$376K	0.02%	287
2020 Q3	$13.7M	Sell	383,727 -56,914	-13%	-$1.71M	0.01%	347
2020 Q2	$10.7M	Buy	440,641 +1,762	+0.4%	+$41.4K	0.01%	365
2020 Q1	$7.68M	Buy	+438,879	New	+$9.16M	0.01%	359

Other funds holding DNLI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Jennison Associates's DNLI Position: Q4 2025 in Review

Jennison Associates sold out of Denali Therapeutics (DNLI) in Q4 2025, closing a stake of 45,445 shares — an estimated $660K sold.

Jennison Associates first reported a position in DNLI in Q1 2020 and held it in 9 quarters. The position peaked at $31.6M in Q4 2020. 250 funds tracked by Wall St. Rank hold DNLI as of Q4 2025.

Jennison Associates reported no remaining Denali Therapeutics position as of Q4 2025 after selling out during the quarter.
Jennison Associates sold 45,445 Denali Therapeutics shares in Q4 2025, an estimated $660K.
Jennison Associates first reported a position in Denali Therapeutics in Q1 2020 and held it in 9 quarters.
Jennison Associates's Denali Therapeutics position peaked at $31.6M in Q4 2020.
250 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2025.

Based on Jennison Associates's 13F filing for Q4 2025, filed 30 Jan 2026.